Introduction
The EAU Working Party on Muscle-invasive and Metastatic Bladder Cancer has published guidelines comprising risk factors, diagnostic workup, classification, treatment, quality of life and follow-up.
Most of the recommendations are based on the results of well conducted clinical studies. Due to the nature of the disease there are only few randomized trials or meta-analyses which can be considered for reference.
The recommendations of the working party concern transitional cell cancer (90% of all bladder carcinomas) invading muscle and beyond, as well as metastatic tumours. 
Diagnosis and Staging
TUR and bimanual palpation are the essentials for the assessment of the local tumour. Superficial and deep areas of the tumour have to be sent separately for pathohistological examination. CT or MRI are helpful to monitor patients undergoing neo-adjuvant chemotherapy or bladder sparing treatment. Lymphadenectomy of the pelvic lymph nodes is the only method to accurately assess lymph node involvement.
Recommendations for diagnosis and staging:
mandatory clinical evaluations • TUR and bimanual examination.
• Biopsy of tumour base, prostatic urethra and bladder neck.
• Chest-X-ray.
• IVP or sonography. mandatory pathological evaluations • Depth of invasion.
• Assessment of margins.
• Histological subtyping.
• Extensive lymph node representation.
Treatment of local tumour
• Radical cystectomy with resection of the lymph nodes within the true pelvis up to the bifurcation of the iliac vessels is the standard of care for muscle-invasive tumours (T2-T4a,N0, M0).
• Radiotherapy with or without concomitant chemotherapy as well as bladder sparing surgery together with neoadjuvant and adjuvant chemotherapy may be considered as reasonable alternatives in special situations.
• Salvage cystectomy can be attempted in the case of persistent disease. Performance status, co-morbidity and age can influence the choice of therapy. In radical cystectomy the bladder, as well as neighbouring organs, such as the prostate, seminal vesicles, uterus, part of the vagina and adnexa, is removed. The urethra can be preserved in case the margins are negative. The extent of lymphadenectomy is currently under discussion favouring the extended type including lymph nodes as far as the aortic bifurcation.
• Neoadjuvant chemotherapy with radical cystectomy has provided only a minimal benefit. • Trials on adjuvant chemotherapy in high risk patients (T3-T4) or metastases to the lymph nodes provide controversial results and therefore the decision for the individual patient should be based on knowledge of the relapse rate per pathological stage.
Recommendations for treatment of local tumour:
• Radical cystectomy in T2-T4a, N0,M0.
• Radiotherapy with or without chemotherapy for bladder preservation or advanced stage T4b or significant co-morbidity.
• Palliative radiotherapy for uncontrollable local symptoms.
• Adjuvant chemotherapy in individual patients.
Treatment of metastatic disease
Systemic chemotherapy in patients with metastatic transitional cell carcinoma can induce tumour remission in as much as 70% of patients. However, cure is rarely obtained. Prognostic factors that predict response to chemotherapy include alkaline phosphatase, age greater than 60 years, performance status and visceral metastasis. Up-front chemotherapy with secondary surgery in case of remission can be considered.
Modern polychemotherapy protocols include cisplatin, gemcitabine, vinblastine, methotrexate and Taxol.
Recommendation for treatment of metastatic disease
• Cisplatin-containing polychemotherapy in metastatic disease with favourable prognosis.
Urinary diversion after radical cystectomy
Four treatment options are presently considered. Ileal conduit, orthotopic bladder substitution, continent reservoir and ureterosigmoidostomy. Each has specific advantages and disadvantages. Bladder substitution is the first option in many centres. The overall long-term outcome in terms of quality of life is good, and social, physical and functional activities are only moderately impaired.
Contraindications for more complex procedures are debilitating neurological or psychiatric illness, short life expectancy and impaired liver and renal function.
Contraindications for orthotopic bladder substitution are TCC of the prostatic urethra or bladder neck (female), widespread Tis, high-dose preoperative irradiation, complex urethral stricture and pre-existing incontinence (female).
Recommendations for urinary diversion after radical cystectomy
• Patients planned for cystectomy should be informed of the possible types of urinary diversions.
• The final decision has to based on a consensus between patient and surgeon.
